| Year |
Citation |
Score |
| 2017 |
van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT. Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 17: 15. PMID 28545563 DOI: 10.1186/S40644-017-0117-5 |
0.34 |
|
| 2017 |
Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, Rutgers EJT, Valdés Olmos RA, Sonke GS, Rodenhuis S, Vrancken Peeters MJTFD, Gilhuijs KGA. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. Plos One. 12: e0176782. PMID 28531188 DOI: 10.1371/Journal.Pone.0176782 |
0.343 |
|
| 2017 |
van Ramshorst MS, van Werkhoven E, Mandjes IA, Schot M, Wesseling J, Vrancken Peeters MT, Meerum Terwogt JM, Bos ME, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS. Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. European Journal of Cancer (Oxford, England : 1990). 74: 47-54. PMID 28335887 DOI: 10.1016/J.Ejca.2016.12.023 |
0.39 |
|
| 2017 |
Lips E, Hoogstraat M, Mulder L, Nederlof P, Sonke G, Rodenhuis S, Wesseling J, Wessels L. Abstract PD1-07: Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd1-07 |
0.332 |
|
| 2017 |
Rossum Av, Oosterkamp H, Werkhoven Ev, Opdam M, Mandjes I, Leeuwen-Stok Ev, Tinteren Hv, Kok M, Imholz A, Portielje J, Bos M, Bochove Av, Wesseling J, Rutgers E, Rodenhuis S, et al. Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04) Cancer Research. DOI: 10.1158/1538-7445.Sabcs16-P5-14-03 |
0.41 |
|
| 2017 |
Steenbruggen T, Ramshorst v, Stouthard J, Rodenhuis S, Linn S, Sonke G, Smorenburg C. Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-21-30 |
0.405 |
|
| 2017 |
Lips EH, Mooyaart AL, Seijen Mv, Mulder L, Hoogstraat M, Nederlof PM, Wessels LF, Rodenhuis S, Sonke GS, Wesseling J. Abstract 1751: Systematic bias in genomic breast cancer classification due to selecting cases with high tumor percentage and good RNA quality Cancer Research. 77: 1751-1751. DOI: 10.1158/1538-7445.Am2017-1751 |
0.304 |
|
| 2016 |
Teixeira SC, Koolen BB, Elkhuizen PH, Vrancken Peeters MT, Stokkel MP, Rodenhuis S, van der Noort V, Rutgers EJ, Valdés Olmos RA. PET/CT with F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 43: 625-635. PMID 27847287 DOI: 10.1016/J.Ejso.2016.10.012 |
0.33 |
|
| 2016 |
Loo CE, Rigter LS, Pengel KE, Wesseling J, Rodenhuis S, Peeters MJ, Sikorska K, Gilhuijs KG. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Breast Cancer Research : Bcr. 18: 82. PMID 27495815 DOI: 10.1186/S13058-016-0742-0 |
0.376 |
|
| 2016 |
Ramshorst v, Werkhoven Ev, Mandjes I, Schot M, Wesseling J, Peeters MV, Rodenhuis S, Oosterkamp H, Bos M, Terwogt JM, Linn S, Sonke G. Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-14-16 |
0.494 |
|
| 2016 |
Hoogstraat M, Lips E, Mulder L, Nederlof P, Sonke G, Rodenhuis S, Wesseling J, Wessels L. Comprehensive characterization of matched pre-treatment biopsies and residual disease of chemotherapy treated breast cancer European Journal of Cancer. 61: S30. DOI: 10.1016/S0959-8049(16)61092-4 |
0.391 |
|
| 2015 |
Steenbruggen TG, Linn SC, Rodenhuis S, Sonke GS. Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient? CurēUs. 7: e433. PMID 26848422 DOI: 10.7759/Cureus.433 |
0.457 |
|
| 2015 |
Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Research : Bcr. 17: 134. PMID 26433948 DOI: 10.1186/S13058-015-0642-8 |
0.4 |
|
| 2015 |
Jebbink M, van Werkhoven E, Mandjes IA, Wesseling J, Lips EH, Vrancken Peeters MJ, Loo CE, Sonke GS, Linn SC, Falo Zamora C, Rodenhuis S. The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure. Breast Cancer Research and Treatment. 153: 145-52. PMID 26210520 DOI: 10.1007/S10549-015-3510-4 |
0.438 |
|
| 2015 |
Lips EH, Michaut M, Hoogstraat ML, Mulder L, Besselink N, Koudijs MJ, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF. Abstract P3-06-21: Next generation sequencing to find predictors for chemotherapy response in triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-21 |
0.366 |
|
| 2014 |
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Wesseling J, vd Vijver MJ, de Vries EGE, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy Breast Cancer Research. 16. PMID 24887359 DOI: 10.1186/Bcr3655 |
0.365 |
|
| 2014 |
Pengel KE, Koolen BB, Loo CE, Vogel WV, Wesseling J, Lips EH, Rutgers EJT, Valdés Olmos RA, Vrancken Peeters MJTFD, Rodenhuis S, Gilhuijs KGA. Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy European Journal of Nuclear Medicine and Molecular Imaging. 41: 1515-1524. PMID 24777490 DOI: 10.1007/S00259-014-2770-2 |
0.358 |
|
| 2014 |
De Ronde JJ, Bonder MJ, Lips EH, Rodenhuis S, Wessels LFA. Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes Plos One. 9. PMID 24558399 DOI: 10.1371/Journal.Pone.0088551 |
0.391 |
|
| 2014 |
Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging. 41: 32-40. PMID 23929431 DOI: 10.1007/S00259-013-2515-7 |
0.337 |
|
| 2013 |
Rigter LS, Loo CE, Linn SC, Sonke GS, Van Werkhoven E, Lips EH, Warnars HA, Doll PK, Bruining A, Mandjes IA, Vrancken Peeters MJ, Wesseling J, Gilhuijs KG, Rodenhuis S. Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer British Journal of Cancer. 109: 2965-2972. PMID 24149178 DOI: 10.1038/Bjc.2013.661 |
0.411 |
|
| 2013 |
Koolen BB, Valdés Olmos RA, Vogel WV, Vrancken Peeters MJTFD, Rodenhuis S, Rutgers EJT, Elkhuizen PHM. Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy Breast Cancer Research and Treatment. 141: 249-254. PMID 24002735 DOI: 10.1007/S10549-013-2678-8 |
0.345 |
|
| 2013 |
Lips EH, Mulder L, De Ronde JJ, Mandjes IAM, Koolen BB, Wessels LFA, Rodenhuis S, Wesseling J. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response Breast Cancer Research and Treatment. 140: 63-71. PMID 23828499 DOI: 10.1007/S10549-013-2620-0 |
0.413 |
|
| 2013 |
Sonke GS, Mandjes IA, Holtkamp MJ, Schot M, Van Werkhoven E, Wesseling J, Vrancken Peeters MJ, Rodenhuis S, Linn SC. Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer Breast Journal. 19: 419-426. PMID 23682812 DOI: 10.1111/Tbj.12124 |
0.479 |
|
| 2013 |
Lips EH, Mulder L, Oonk A, Van Der Kolk LE, Hogervorst FBL, Imholz ALT, Wesseling J, Rodenhuis S, Nederlof PM. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers British Journal of Cancer. 108: 2172-2177. PMID 23558900 DOI: 10.1038/Bjc.2013.144 |
0.356 |
|
| 2013 |
Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vrancken Peeters MJ. Early assessment of axillary response with ¹â¸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Annals of Surgical Oncology. 20: 2227-35. PMID 23456316 DOI: 10.1245/S10434-013-2902-0 |
0.326 |
|
| 2013 |
Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast (Edinburgh, Scotland). 22: 691-7. PMID 23414930 DOI: 10.1016/J.Breast.2012.12.020 |
0.369 |
|
| 2013 |
de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment. 137: 213-23. PMID 23203637 DOI: 10.1007/S10549-012-2340-X |
0.408 |
|
| 2013 |
Giesen E, Mager A, van Tinteren H, Rodenhuis S, Kerst JM. An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy Urologic Oncology: Seminars and Original Investigations. 31: 110-114. PMID 21458311 DOI: 10.1016/J.Urolonc.2010.10.006 |
0.356 |
|
| 2013 |
Lips EH, Michaut M, Mulder L, Besselink N, Hoogstraat ML, Koudijs MJ, Voest EE, Bernards R, Wesseling J, Wessels LFA, Rodenhuis S. Next-generation sequencing to find predictors for chemotherapy response in triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 31: 1010-1010. DOI: 10.1200/Jco.2013.31.15_Suppl.1010 |
0.397 |
|
| 2013 |
Lips EH, Mulder L, Kolk LEvd, Oonk AMM, Imholz ALT, Hogervorst FBL, Wesseling J, Rodenhuis S, Nederlof PM. Abstract 1192: Triple negative breast cancer: BRCAness and concordance of clinical features and treatment response with BRCA1 mutation carriers. Cancer Research. 73: 1192-1192. DOI: 10.1158/1538-7445.Am2013-1192 |
0.369 |
|
| 2013 |
Ramshorst v, Thienen Jv, Stouthard J, Rodenhuis S, Linn S, Sonke G. Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot1-1-01 |
0.465 |
|
| 2012 |
Koolen B, Rutgers EJ, Rodenhuis S, Valdés Olmos RO. Clinical relevance of the use of FDG PET/CT in locally advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 195. PMID 28146836 DOI: 10.1200/Jco.2012.30.27_Suppl.195 |
0.389 |
|
| 2012 |
Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Research and Treatment. 136: 35-43. PMID 22961065 DOI: 10.1007/S10549-012-2233-Z |
0.354 |
|
| 2012 |
Koolen BB, Vrancken Peeters MJTFD, Wesseling J, Lips EH, Vogel WV, Aukema TS, Van Werkhoven E, Gilhuijs KGA, Rodenhuis S, Rutgers EJT, Valdés Olmos RA. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy European Journal of Nuclear Medicine and Molecular Imaging. 39: 1830-1838. PMID 22895862 DOI: 10.1007/S00259-012-2211-Z |
0.36 |
|
| 2012 |
Koolen BB, Valdés Olmos RA, Elkhuizen PHM, Vogel WV, Vrancken Peeters MJTFD, Rodenhuis S, Rutgers EJT. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy Breast Cancer Research and Treatment. 135: 231-240. PMID 22872522 DOI: 10.1007/S10549-012-2179-1 |
0.346 |
|
| 2012 |
Oonk AMM, Van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz ALT, Lips EH. Clinical correlates of 'brcaness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy Annals of Oncology. 23: 2301-2305. PMID 22357256 DOI: 10.1093/Annonc/Mdr621 |
0.473 |
|
| 2012 |
Koolen BB, Vrancken Peeters MJTFD, Aukema TS, Vogel WV, Oldenburg HSA, Van Der Hage JA, Hoefnagel CA, Stokkel MPM, Loo CE, Rodenhuis S, Rutgers EJT, Valdés Olmos RA. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: Comparison with conventional imaging techniques Breast Cancer Research and Treatment. 131: 117-126. PMID 21935602 DOI: 10.1007/S10549-011-1767-9 |
0.312 |
|
| 2012 |
Lips EH, Mulder L, De Ronde JJ, Mandjes IAM, Vincent A, Vrancken Peeters MTFD, Nederlof PM, Wesseling J, Rodenhuis S. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: Response prediction based on immunohistochemical and molecular characteristics Breast Cancer Research and Treatment. 131: 827-836. PMID 21472434 DOI: 10.1007/S10549-011-1488-0 |
0.375 |
|
| 2012 |
Penel N, Demetri GD, Blay J, Cousin S, Maki RG, Chawla SP, Judson IR, von Mehren M, Schoffski P, Verweij J, Casali PG, Rodenhuis S, Gomez J, Nieto A, Zintl P, et al. Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. Journal of Clinical Oncology. 30: 10013-10013. DOI: 10.1200/Jco.2012.30.15_Suppl.10013 |
0.377 |
|
| 2012 |
Koolen B, Valdés OR, Vogel W, Vrancken PM, Rodenhuis S, Rutgers E, Elkhuizen P. Abstract P4-02-01: 18F-FDG PET/CT for the assessment of locoregional lymph node involvement and radiotherapy indication in stage II-III breast cancer treated with neoadjuvant chemotherapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-02-01 |
0.33 |
|
| 2012 |
Koolen B, Pengel K, Wesseling J, Vogel W, Peeters MV, Vincent A, Gilhuijs K, Rodenhuis S, Rutgers E, Olmos RV. 139. Relevance of breast cancer subtypes in response monitoring with 18F-FDG PET/CT during neoadjuvant chemotherapy European Journal of Surgical Oncology. 38: 777-778. DOI: 10.1016/S0959-8049(12)70075-8 |
0.324 |
|
| 2012 |
Koolen B, Olmos RV, Elkhuizen P, Vogel W, Peeters MV, Rodenhuis S, Rutgers E. 155. Locoregional lymph node involvement on 18F-FDG PET/CT and estimation of risk for locoregional recurrence in stage II–III breast cancer patients European Journal of Surgical Oncology. 38: 783. DOI: 10.1016/J.Ejso.2012.06.154 |
0.309 |
|
| 2011 |
Lips EH, Mulder L, Joosse SA, Savola S, Vollebergh MA, Wessels LF, Wesseling J, Nederlof PM, Rodenhuis S. Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness, and as such treatment response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10513. PMID 28021787 DOI: 10.1200/Jco.2011.29.15_Suppl.10513 |
0.368 |
|
| 2011 |
Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AMM, Imholz ALT, Wessels LFA, Wesseling J, Nederlof PM, Rodenhuis S. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness Breast Cancer Research. R107. PMID 22032731 DOI: 10.1186/Bcr3049 |
0.367 |
|
| 2011 |
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3214-23. PMID 21768471 DOI: 10.1200/Jco.2010.32.5910 |
0.417 |
|
| 2011 |
Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJTFD, Gilhuijs KGA. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: Relevance of Breast Cancer Subtype Journal of Clinical Oncology. 29: 660-666. PMID 21220595 DOI: 10.1200/Jco.2010.31.1258 |
0.359 |
|
| 2011 |
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, ... ... Rodenhuis S, et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients Annals of Oncology. 22: 1561-1570. PMID 21135055 DOI: 10.1093/Annonc/Mdq624 |
0.439 |
|
| 2011 |
Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy Annals of Oncology. 22: 870-876. PMID 20937646 DOI: 10.1093/Annonc/Mdq468 |
0.39 |
|
| 2011 |
Linn SC, Lips EH, Nederlof PM, Wessels LF, Wesseling J, van de Vijver M, De Vries E, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Vollebergh MA. Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer. Journal of Clinical Oncology. 29: 10505-10505. DOI: 10.1200/Jco.2011.29.15_Suppl.10505 |
0.396 |
|
| 2011 |
Lips EH, Mulder L, Ronde JJD, Mandjes IAM, Vincent AA, Vrancken-Peeters MTFD, Nederlof PM, Wesseling J, Rodenhuis S. Abstract 3134: Neoadjuvant chemotherapy in ER+HER2- breast cancer: Response prediction based on immunohistochemical and molecular characteristics Cancer Research. 71: 3134-3134. DOI: 10.1158/1538-7445.Am2011-3134 |
0.38 |
|
| 2011 |
Ronde JD, Mulder L, Lips E, Rodenhuis S, Wessels L. Abstract 22: Identifying chemotherapy resistance genes using outlier detection Cancer Research. 71: 22-22. DOI: 10.1158/1538-7445.Am2011-22 |
0.305 |
|
| 2011 |
Wesseling J, Lips E, Oonk A, Smits R, Rijn Cv, Mulder L, Laddach N, Savola S, Wessels L, Nederlof P, Rodenhuis S, Imholz A. PD03-08: BRCA1-Like Triple Negative Tumors: Clinicopathological Variables and Chemosensitivity to Alkylating Agents. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd03-08 |
0.394 |
|
| 2011 |
Sonke G, Mandjes I, Holtkamp M, Schot M, Oosterkamp H, Wesseling J, Vrancken PM, Rodenhuis S, Linn S. P3-14-17: Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2−Positive Breast Cancer: The TRAIN Study. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-14-17 |
0.491 |
|
| 2011 |
Mukhtar R, Lips E, Wesseling J, Livasy C, Yau C, Berry D, Veer Lv, Carey L, Esserman L, Rodenhuis S, Hwang E. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-10 |
0.399 |
|
| 2010 |
Straver ME, Rutgers EJT, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HSA, Antonini N, Vrancken Peeters MTFD. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy Annals of Surgical Oncology. 17: 2411-2418. PMID 20373039 DOI: 10.1245/S10434-010-1008-1 |
0.382 |
|
| 2010 |
Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). European Journal of Cancer (Oxford, England : 1990). 46: 72-83. PMID 19853437 DOI: 10.1016/J.Ejca.2009.09.022 |
0.315 |
|
| 2010 |
De Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJTFD, Wesseling J, Van De Vijver M, Wessels LFA, Rodenhuis S. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response Breast Cancer Research and Treatment. 119: 119-126. PMID 19669409 DOI: 10.1007/S10549-009-0499-6 |
0.356 |
|
| 2010 |
Straver ME, Glas AM, Hannemann J, Wesseling J, Van De Vijver MJ, Rutgers EJT, Vrancken Peeters MJTFD, Van Tinteren H, Van'T Veer LJ, Rodenhuis S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer Breast Cancer Research and Treatment. 119: 551-558. PMID 19214742 DOI: 10.1007/S10549-009-0333-1 |
0.386 |
|
| 2010 |
Vollebergh MA, Nederlof PM, Wessels LF, Schmidt MK, Beers Ev, Holtkamp M, Froklage FE, Vries EGEd, Schrama JG, Wesseling J, Vijver MJvd, Tinteren Hv, Bruin Md, Hauptmann M, Rodenhuis S, et al. Abstract 4820: A clinical test for BRCAness: Using array comparative genomic hybridization to predict benefit of high-dose, platinum-containing chemotherapy in ER-low/HER2-negative breast cancer patients Cancer Research. 70: 4820-4820. DOI: 10.1158/1538-7445.Am10-4820 |
0.442 |
|
| 2010 |
Lips E, Mulder L, Hannemann J, Laddach N, Vrancken-Peeters M, Vijver Mvd, Wesseling J, Nederlof P, Rodenhuis S. Abstract PD07-07: Indicators of Homologous Recombination Deficiency in Breast Cancer and Association with Response to Neoadjuvant Chemotherapy Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd07-07 |
0.394 |
|
| 2010 |
Wesseling J, Vollebergh M, Hauptmann M, Wessels L, Nederlof P, Vries Ed, Rodenhuis S, Vijver Mvd, Linn S. Abstract PD01-04: Histological Features of ER-Low, HER2-Negative Breast Cancer Predict Response to High Dose, Platinum-Based Chemotherapy Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd01-04 |
0.4 |
|
| 2010 |
Lips E, Mulder L, Hannemann J, Peeters MV, van de Vijver M, Wesseling J, Nederlof P, Rodenhuis S. 10 Homologous recombination deficiency in breast cancer and association with response to neo-adjuvant chemotherapy European Journal of Cancer Supplements. 8: 60-61. DOI: 10.1016/S1359-6349(10)70042-2 |
0.386 |
|
| 2009 |
Rodenhuis S, Mandjes IAM, Wesseling J, van de Vijver MJ, Peeters MJTDFV, Sonke GS, Linn SC. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy Annals of Oncology. 21: 481-487. PMID 19717533 DOI: 10.1093/Annonc/Mdp348 |
0.4 |
|
| 2009 |
Straver ME, Rutgers EJT, Russell NS, Oldenburg HSA, Rodenhuis S, Wesseling J, Vincent A, Peeters MTFDV. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer European Journal of Cancer. 45: 2284-2292. PMID 19464164 DOI: 10.1016/J.Ejca.2009.04.029 |
0.43 |
|
| 2009 |
Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen Therapeutic Drug Monitoring. 31: 95-103. PMID 19155964 DOI: 10.1097/Ftd.0B013E318194E484 |
0.533 |
|
| 2009 |
Ekhart C, Doodeman VD, Rodenhuis S, Smits PHM, Beijnen JH, Huitema ADR. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa British Journal of Clinical Pharmacology. 67: 50-60. PMID 19076156 DOI: 10.1111/J.1365-2125.2008.03321.X |
0.45 |
|
| 2009 |
Ekhart C, Rodenhuis S, Schellens JHM, Beijnen JH, Huitema ADR. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemotherapy and Pharmacology. 64: 115-122. PMID 18989671 DOI: 10.1007/S00280-008-0856-X |
0.415 |
|
| 2009 |
Ekhart C, Rodenhuis S, Smits PHM, Beijnen JH, Huitema ADR. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment Cancer Treatment Reviews. 35: 18-31. PMID 18771857 DOI: 10.1016/J.Ctrv.2008.07.003 |
0.429 |
|
| 2009 |
Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR. Carbamazepine induces bioactivation of cyclophosphamide and thiotepa Cancer Chemotherapy and Pharmacology. 63: 543-547. PMID 18437385 DOI: 10.1007/S00280-008-0758-Y |
0.54 |
|
| 2009 |
Ekhart C, Kerst JM, Rodenhuis S, Beijnen JH, Huitema ADR. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency Cancer Chemotherapy and Pharmacology. 63: 375-379. PMID 18431571 DOI: 10.1007/S00280-008-0757-Z |
0.513 |
|
| 2009 |
Linn SC, Vollebergh MA, Hauptmann M, Wessels LF, Nederlof PM, de Vries EG, Rodenhuis S, Wesseling J. Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology Journal of Clinical Oncology. 27: 587-587. DOI: 10.1200/Jco.2009.27.15_Suppl.587 |
0.444 |
|
| 2009 |
Vollebergh M, Nederlof P, Wessels L, Schmidt M, Joosse S, Beers Ev, Froklage F, Holtkamp M, Schrama J, Wesseling J, Hauptmann M, Bruin Md, Rodenhuis S, Linn S. Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. Cancer Research. 69: 6050. DOI: 10.1158/0008-5472.Sabcs-6050 |
0.428 |
|
| 2009 |
Knauer M, Retèl V, Bueno-de-Mesquita JM, Rutgers EJT, Harten WHv, Rodenhuis S, Vijver MJvd, Veer LJv', Linn SC. Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer. Cancer Research. 69: 1084. DOI: 10.1158/0008-5472.Sabcs-1084 |
0.374 |
|
| 2009 |
Knauer M, Straver M, Rutgers E, Bender R, Cardoso F, Mook S, van de Vijver M, Saghatchian M, Koornstra R, Bueno-de-Mesquita J, Rodenhuis S, Linn S, van 't Veer L. 0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer The Breast. 18: S36-S37. DOI: 10.1016/S0960-9776(09)70118-3 |
0.379 |
|
| 2008 |
Gast MCW, van Tinteren H, Bontenbal M, van Hoesel RQGCM, Nooij MA, Rodenhuis S, Span PN, Tjan-Heijnen VCG, de Vries EGE, Harris N, Twisk JWR, Schellens JHM, Beijnen JH. Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients Bmc Cancer. 8. PMID 19108738 DOI: 10.1186/1471-2407-8-389 |
0.499 |
|
| 2008 |
Loo CE, Teertstra HJ, Rodenhuis S, Van De Vijver MJ, Hannemann J, Muller SH, Peeters MJV, Gilhuijs KGA. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: Initial results American Journal of Roentgenology. 191: 1331-1338. PMID 18941065 DOI: 10.2214/Ajr.07.3567 |
0.384 |
|
| 2008 |
Ekhart C, Rodenhuis S, Smits PHM, Beijnen JH, Huitema ADR. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin Pharmacogenetics and Genomics. 18: 1009-1015. PMID 18854779 DOI: 10.1097/Fpc.0B013E328313Aaa4 |
0.501 |
|
| 2008 |
Nieboer P, de Vries EGE, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, Voest EE, Nooij MA, Boezen HM, van der Graaf WTA. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients Bone Marrow Transplantation. 42: 475-481. PMID 18622420 DOI: 10.1038/Bmt.2008.195 |
0.399 |
|
| 2008 |
Ekhart C, Doodeman VD, Rodenhuis S, Smits PHM, Beijnen JH, Huitema ADR. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide Pharmacogenetics and Genomics. 18: 515-523. PMID 18496131 DOI: 10.1097/Fpc.0B013E3282Fc9766 |
0.484 |
|
| 2008 |
Hannemann J, Mulder L, Linn SC, Sonke G, Vijzelaar R, Errami A, Vrancken-Peeters M, van de Vijver MJ, Rodenhuis S. Homologous recombination defects in sporadic breast cancers Journal of Clinical Oncology. 26: 22102-22102. DOI: 10.1200/Jco.2008.26.15_Suppl.22102 |
0.323 |
|
| 2008 |
Hannemann J, Mulder L, Halfwerk H, Linn S, Sonke G, Vijzelaar R, Errami A, Vrancken-Peeters M, Van de Vijver M, Rodenhuis S. Detection of homologous recombination defects in biopsies of sporadic breast cancers European Journal of Cancer Supplements. 6: 139. DOI: 10.1016/S1359-6349(08)70624-4 |
0.332 |
|
| 2008 |
Loo C, Teertstra H, Rodenhuis S, Van de Vijver M, Hannemann J, Muller S, Vrancken Peeters M, Gilhuijs K. Interpretation of contrast enhanced MRI for early prediction of breast-cancer response to neoadjuvant chemotherapy: Initial results European Journal of Cancer Supplements. 6: 112. DOI: 10.1016/S1359-6349(08)70532-9 |
0.382 |
|
| 2008 |
Straver M, Rutgers E, Linn S, Rodenhuis S, Wesseling J, Antonini N, Vrancken Peeters M. Relevance of histological and molecular subtypes in the outcome of primary systemic therapy for operable breast cancer European Journal of Cancer Supplements. 6: 59. DOI: 10.1016/S1359-6349(08)70346-X |
0.323 |
|
| 2007 |
Buijs C, Rodenhuis S, Seynaeve CM, Van Hoesel QGCM, Van Der Wall E, Smit WJM, Nooij MA, Voest E, Hupperets P, TenVergert EM, Van Tinteren H, Willemse PHB, Mourits MJE, Aaronson NK, Post WJ, et al. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life Journal of Clinical Oncology. 25: 5403-5409. PMID 18048822 DOI: 10.1200/Jco.2007.11.2813 |
0.446 |
|
| 2007 |
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, ... ... Rodenhuis S, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) Lancet Oncology. 8: 1079-1087. PMID 18042430 DOI: 10.1016/S1470-2045(07)70346-7 |
0.388 |
|
| 2007 |
Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3144-50. PMID 17634494 DOI: 10.1200/Jco.2006.09.7717 |
0.388 |
|
| 2007 |
Ekhart C, Gebretensae A, Rosing H, Rodenhuis S, Beijnen JH, Huitema ADR. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS) Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 854: 345-349. PMID 17485255 DOI: 10.1016/J.Jchromb.2007.04.024 |
0.398 |
|
| 2007 |
Veltkamp SA, Meerum Terwogt JM, Van Den Heuvel MM, Van Boven HH, Schellens JHM, Rodenhuis S. Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel Investigational New Drugs. 25: 279-281. PMID 17221305 DOI: 10.1007/S10637-006-9030-7 |
0.304 |
|
| 2007 |
Hannemann J, Halfwerk H, Velds A, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Prospective analysis of mRNA expression signatures as predictive tests in primary breast cancer Journal of Clinical Oncology. 25: 2531-2531. DOI: 10.1200/Jco.2007.25.18_Suppl.2531 |
0.432 |
|
| 2006 |
Hannemann J, Kristel P, Van Tinteren H, Bontenbal M, Van Hoesel QGCM, Smit WM, Nooij MA, Voest EE, Van Der Wall E, Hupperets P, De Vries EGE, Rodenhuis S, Van De Vijver MJ. Molecular subtypes of breast cancer and amplification of topoisomerase IIα: Predictive role in dose intensive adjuvant chemotherapy British Journal of Cancer. 95: 1334-1341. PMID 17088909 DOI: 10.1038/Sj.Bjc.6603449 |
0.467 |
|
| 2006 |
Ekhart C, De Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function Clinical Cancer Research. 12: 6502-6508. PMID 17085665 DOI: 10.1158/1078-0432.Ccr-05-1076 |
0.466 |
|
| 2006 |
De Jonge ME, Huitema ADR, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy British Journal of Cancer. 94: 1226-1230. PMID 16622453 DOI: 10.1038/Sj.Bjc.6603097 |
0.525 |
|
| 2006 |
Rodenhuis S, Bontenbal M, van Hoesel QGCM, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de Vries EGE. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Annals of Oncology. 17: 588-596. PMID 16446318 DOI: 10.1093/Annonc/Mdl001 |
0.484 |
|
| 2006 |
Hannemann J, Halfwerk H, Velds A, Loo C, Rutgers E, Rodenhuis S, Van de Vijver M. Prediction of response to neoadjuvant chemotherapy in breast cancer Journal of Clinical Oncology. 24: 20005-20005. DOI: 10.1200/Jco.2006.24.18_Suppl.20005 |
0.456 |
|
| 2006 |
Schornagel JH, Helgason HH, Rodenhuis S, Schellens JH. Fulvestrant in heavily pre-treated breast cancer patients—Single institution experience Journal of Clinical Oncology. 24: 13157-13157. DOI: 10.1200/Jco.2006.24.18_Suppl.13157 |
0.452 |
|
| 2006 |
Ekhart C, Huitema A, Rodenhuis S, Beijnen JH. Impact of polymorphisms in the CYP2B6 gene on the pharmacokinetics of cyclophosphamide and thiotepa Journal of Clinical Oncology. 24: 13062-13062. DOI: 10.1200/Jco.2006.24.18_Suppl.13062 |
0.505 |
|
| 2006 |
Hannemann J, Halfwerk JB, Velds A, Loo C, Rutgers E, Rodenhuis S, van de Vijver MJ. P72. Prediction of response to preoperative chemotherapy in locally advanced breast cancer European Journal of Cancer Supplements. 4: 53. DOI: 10.1016/J.Ejcsup.2006.04.132 |
0.385 |
|
| 2005 |
De Jonge ME, Huitema ADR, Van Dam SM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with thiotepa and carboplatin Therapeutic Drug Monitoring. 27: 756-765. PMID 16306851 DOI: 10.1097/01.Ftd.0000177224.19294.92 |
0.478 |
|
| 2005 |
Göker E, Rodenhuis S. Early onset of oral aphthous ulcers with weekly docetaxel Netherlands Journal of Medicine. 63: 364-366. PMID 16244385 |
0.32 |
|
| 2005 |
De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide Clinical Pharmacokinetics. 44: 1135-1164. PMID 16231966 DOI: 10.2165/00003088-200544110-00003 |
0.453 |
|
| 2005 |
Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LVAM, Van Der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, Van Der Graaf WTA, TenVergert EM, Van Tinteren H, De Vries EGE. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: A longitudinal study Journal of Clinical Oncology. 23: 8296-8304. PMID 16219926 DOI: 10.1200/Jco.2005.10.167 |
0.356 |
|
| 2005 |
Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3331-42. PMID 15908647 DOI: 10.1200/Jco.2005.09.077 |
0.382 |
|
| 2005 |
De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC) Therapeutic Drug Monitoring. 27: 393-402. PMID 15905813 DOI: 10.1097/01.Ftd.0000158081.38330.5E |
0.53 |
|
| 2005 |
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, Haybittle J, Davies C, Harvey V, ... ... Rodenhuis S, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. 365: 1687-1717. PMID 15894097 DOI: 10.1016/S0140-6736(05)66544-0 |
0.368 |
|
| 2005 |
De Jonge ME, Huitema ADR, Holtkamp MJ, Van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism Cancer Chemotherapy and Pharmacology. 56: 370-378. PMID 15838656 DOI: 10.1007/S00280-005-1005-4 |
0.533 |
|
| 2005 |
De Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL British Journal of Clinical Pharmacology. 59: 325-334. PMID 15752379 DOI: 10.1111/J.1365-2125.2004.02325.X |
0.491 |
|
| 2005 |
De Jonge ME, Huitema ADR, Van Dam SM, Rodenhuis S, Beijnen JH. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes Anti-Cancer Drugs. 16: 331-336. PMID 15711186 DOI: 10.1097/00001813-200503000-00013 |
0.452 |
|
| 2005 |
De Jonge ME, Huitema ADR, Van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin Cancer Chemotherapy and Pharmacology. 55: 507-510. PMID 15685452 DOI: 10.1007/S00280-004-0922-Y |
0.525 |
|
| 2005 |
De Jonge ME, Huitema ADR, Tukker AC, Van Dam SM, Rodenhuis S, Beijnen JH. Accuracy, feasibility, and clinical impact of prospective bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy Clinical Cancer Research. 11: 273-283. PMID 15671556 |
0.465 |
|
| 2005 |
Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 576-84. PMID 15659504 DOI: 10.1200/Jco.2005.01.180 |
0.342 |
|
| 2005 |
De Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review Clinical Pharmacokinetics. 44: 147-173. PMID 15656695 DOI: 10.2165/00003088-200544020-00002 |
0.496 |
|
| 2005 |
Rodenhuis S. Is high-dose chemotherapy dead? European Journal of Cancer. 41: 9-11. PMID 15617985 DOI: 10.1016/J.Ejca.2004.09.014 |
0.485 |
|
| 2005 |
Rodenhuis S, Bontenbal M, Beex LVAM, Richel DJ, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, van de Vijver M, de Vries EGE. Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: Update of the Dutch Randomized Trial Journal of Clinical Oncology. 23: 672-672. DOI: 10.1200/Jco.2005.23.16_Suppl.672 |
0.491 |
|
| 2005 |
Bosma A, Helgason H, Braaf L, Rodenhuis S, van 't Veer L. Detection of minimal disease in breast cancer Breast Cancer Research. 7. DOI: 10.1186/Bcr1183 |
0.424 |
|
| 2005 |
Jonge MEd, Huitema AD, Tukker AC, Dam SMV, Rodenhuis S, Beijnen JH. Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy Clinical Pharmacology & Therapeutics. 77: 94. DOI: 10.1016/J.Clpt.2004.12.252 |
0.496 |
|
| 2004 |
De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction Journal of Pharmacokinetics and Pharmacodynamics. 31: 135-156. PMID 15379382 DOI: 10.1023/B:Jopa.0000034405.03895.C2 |
0.472 |
|
| 2004 |
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, De Vries EGE, Rodenhuis S, Van De Vijver MJ. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement Clinical Cancer Research. 10: 4457-4463. PMID 15240537 DOI: 10.1158/1078-0432.Ccr-03-0054 |
0.37 |
|
| 2004 |
de Jonge ME, van Dam SM, Hillebrand MJX, Rosing H, Huitema ADR, Rodenhuis S, Beijnen JH. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N″-triethylenethio-phosphoramide (thiotepa) and N,N′,N″-triethylene-phosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry Journal of Mass Spectrometry. 39: 262-271. PMID 15039933 DOI: 10.1002/Jms.570 |
0.438 |
|
| 2004 |
Hannemann J, Oosterkamp R, Bosch C, Witteveen A, Hart A, Velds A, Rutgers E, Rodenhuis S, van de Vijver M. Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer European Journal of Cancer Supplements. 2: 170. DOI: 10.1200/Jco.2004.22.14_Suppl.502 |
0.434 |
|
| 2004 |
Faneyte I, Peterse J, Van Tinteren H, Pronk C, De Vries E, Rodenhuis S, van de Vijver M. Risk factors for early recurrences after conventional- or high-dose adjuvant chemotherapy in breast cancer patients with extensive lymph node involvement European Journal of Cancer Supplements. 2: 176. DOI: 10.1016/S1359-6349(04)91016-6 |
0.415 |
|
| 2003 |
Wheatley K, Gray RG, Ives NJ, Tartarone A, Iodice G, Di Renzo N, Mangano MM, Dazzi C, Cariello A, Rodenhuis S, Van Tinteren H, De Vries EGE, Tallman MS, Robert NJ, Lazarus HM, et al. High-dose chemotherapy for breast cancer [1] (multiple letters) New England Journal of Medicine. 349: 1476-1479. PMID 14535260 DOI: 10.1056/NEJM200310093491515 |
0.34 |
|
| 2003 |
Verweij J, Van Oosterom A, Blay JY, Judson I, Rodenhuis S, Van Der Graaf W, Radford J, Le Cesne A, Hogendoorn PCW, Di Paola ED, Brown M, Nielsen OS. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study European Journal of Cancer. 39: 2006-2011. PMID 12957454 DOI: 10.1016/S0959-8049(02)00836-5 |
0.409 |
|
| 2003 |
Schrama JG, De Boer MMD, Baars JW, Schornagel JH, Rodenhuis S. Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer - Toxicity and efficacy Anticancer Research. 23: 2795-2800. PMID 12926115 |
0.393 |
|
| 2003 |
Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. The New England Journal of Medicine. 349: 7-16. PMID 12840087 DOI: 10.1056/Nejmoa022794 |
0.466 |
|
| 2003 |
Schrama JG, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): The Netherlands Cancer Institute experience British Journal of Cancer. 88: 1831-1838. PMID 12799623 DOI: 10.1038/Sj.Bjc.6601001 |
0.45 |
|
| 2003 |
De Jonge ME, Mathôt RAA, Van Dam SM, Rodenhuis S, Beijnen JH. Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels Therapeutic Drug Monitoring. 25: 261-263. PMID 12766550 DOI: 10.1097/00007691-200306000-00002 |
0.4 |
|
| 2003 |
Weigelt B, Bosma AJ, Hart AAM, Rodenhuis S, Van't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients British Journal of Cancer. 88: 1091-1094. PMID 12671691 DOI: 10.1038/Sj.Bjc.6600868 |
0.409 |
|
| 2003 |
Schrama JG, Rodenhuis S, de Gast GC. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer Bone Marrow Transplantation. 31: 141-142. PMID 12621498 DOI: 10.1038/Sj.Bmt.1703801 |
0.369 |
|
| 2003 |
Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, Van De Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome British Journal of Cancer. 88: 406-412. PMID 12569384 DOI: 10.1038/Sj.Bjc.6600749 |
0.394 |
|
| 2002 |
Van De Vijver MJ, He YD, Van 'T Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, ... ... Rodenhuis S, et al. A gene-expression signature as a predictor of survival in breast cancer New England Journal of Medicine. 347: 1999-2009. PMID 12490681 DOI: 10.1056/Nejmoa021967 |
0.391 |
|
| 2002 |
de Jonge ME, Mathôt RAA, Dalesio O, Huitema ADR, Rodenhuis S, Beijnen JH. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy Bone Marrow Transplantation. 30: 593-597. PMID 12407434 DOI: 10.1038/Sj.Bmt.1703695 |
0.531 |
|
| 2002 |
De Jonge ME, Mathôt RA, Van Dam SM, Beijnen JH, Rodenhuis S. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin Cancer Chemotherapy and Pharmacology. 50: 251-255. PMID 12203108 DOI: 10.1007/S00280-002-0494-7 |
0.656 |
|
| 2002 |
Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, Van Rhijn D, Rodenhuis S, Van Dam FSAM. Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients Annals of Oncology. 13: 1387-1397. PMID 12196364 DOI: 10.1093/Annonc/Mdf241 |
0.423 |
|
| 2002 |
Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJT, Richel DJ, Rodenhuis S. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up Annals of Oncology. 13: 689-698. PMID 12075736 DOI: 10.1093/Annonc/Mdf203 |
0.455 |
|
| 2002 |
Huitema ADR, Spaander M, Mathôt RAA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin Annals of Oncology. 13: 374-384. PMID 11996467 DOI: 10.1093/Annonc/Mdf052 |
0.558 |
|
| 2002 |
de Gast GC, Vyth-Dreese FA, Nooijen W, van den Bogaard CJ, Sein J, Holtkamp MM, Linthorst GA, Baars JW, Schornagel JH, Rodenhuis S. Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 58-64. PMID 11773154 DOI: 10.1200/Jco.20.1.58 |
0.317 |
|
| 2001 |
Huitema AD, Mathôt RA, Tibben MM, Rodenhuis S, Beijnen JH. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Therapeutic Drug Monitoring. 23: 650-7. PMID 11802099 DOI: 10.1097/00007691-200112000-00010 |
0.711 |
|
| 2001 |
Kerbusch T, Mathĵt RA, Keizer HJ, Ouwerkerk J, Rodenhuis S, Schellens JH, Beijnen JH. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. European Journal of Clinical Pharmacology. 57: 467-77. PMID 11699611 DOI: 10.1007/S002280100322 |
0.446 |
|
| 2001 |
Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplantation. 28: 173-80. PMID 11509935 DOI: 10.1038/Sj.Bmt.1703105 |
0.568 |
|
| 2001 |
Huitema AD, Mathôt RA, Tibben MM, Rodenhuis S, Beijnen JH. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. Journal of Pharmacokinetics and Pharmacodynamics. 28: 211-30. PMID 11468938 DOI: 10.1023/A:1011543508731 |
0.686 |
|
| 2001 |
van Maanen MJ, Huitema AD, Rodenhuis S, Beijnen JH. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin. Anti-Cancer Drugs. 12: 519-24. PMID 11459998 DOI: 10.1097/00001813-200107000-00005 |
0.504 |
|
| 2001 |
Huitema AD, Reinders C, Tibben MM, Rodenhuis S, Beijnen JH. Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma. Journal of Chromatography. B, Biomedical Sciences and Applications. 757: 349-57. PMID 11417881 DOI: 10.1016/S0378-4347(01)00178-5 |
0.43 |
|
| 2001 |
Rodenhuis S. High-dose chemotherapy in breast cancer--interpretation of the randomized trials. Anti-Cancer Drugs. 12: 85-8. PMID 11261891 DOI: 10.1097/00001813-200102000-00001 |
0.456 |
|
| 2001 |
Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. British Journal of Clinical Pharmacology. 51: 61-70. PMID 11167666 DOI: 10.1046/J.1365-2125.2001.01301.X |
0.705 |
|
| 2001 |
Rodenhuis S, van Tinteren H, de Vries E. High-dose chemotherapy in breast cancer: Dutch randomized studies Breast Cancer Research. 3. DOI: 10.1186/Bcr382 |
0.484 |
|
| 2001 |
de Vries E, Bontendal M, Beex L, van der Wall E, Richel D, Nooij M, Voest E, Hupperets P, Westermann A, Dalesio O, Rodenhuis S. High-dose chemotherapy in breast cancer. The Dutch trial European Journal of Cancer. 37: S285. DOI: 10.1016/S0959-8049(01)81541-0 |
0.44 |
|
| 2000 |
Huitema AD, Tibben MM, Kerbusch T, Kettenes-van den Bosch JJ, Rodenhuis S, Beijnen JH. Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Sciences and Applications. 745: 345-55. PMID 11043753 DOI: 10.1016/S0378-4347(00)00295-4 |
0.442 |
|
| 2000 |
Rodenhuis S. The status of high-dose chemotherapy in breast cancer. The Oncologist. 5: 369-75. PMID 11040272 |
0.347 |
|
| 2000 |
Huitema AD, Smits KD, Mathôt RA, Schellens JH, Rodenhuis S, Beijnen JH. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anti-Cancer Drugs. 11: 515-33. PMID 11036954 DOI: 10.1097/00001813-200008000-00002 |
0.705 |
|
| 2000 |
Huitema AD, Kerbusch T, Tibben MM, Rodenhuis S, Beijnen JH. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemotherapy and Pharmacology. 46: 119-27. PMID 10972481 DOI: 10.1007/S002800000132 |
0.532 |
|
| 2000 |
Westermann AM, Dubbelman R, Baars JP, Moolenaar WH, Beijnen JH, Rodenhuis S. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemotherapy and Pharmacology. 46: 57-62. PMID 10912579 DOI: 10.1007/S002800000116 |
0.538 |
|
| 2000 |
Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 2676-84. PMID 10894866 DOI: 10.1200/Jco.2000.18.14.2676 |
0.465 |
|
| 2000 |
Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clinical Pharmacology and Therapeutics. 67: 621-30. PMID 10872644 DOI: 10.1067/Mcp.2000.106827 |
0.682 |
|
| 2000 |
Rodenhuis S, Huitema AD, van Dam FS, de Vries EG, Beijnen JH. High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer. Cancer Journal (Sudbury, Mass.). 6: S125-30. PMID 10803826 |
0.344 |
|
| 2000 |
Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnen JH. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemotherapy and Pharmacology. 45: 213-8. PMID 10663639 DOI: 10.1007/S002800050032 |
0.48 |
|
| 2000 |
Huitema ADR, Tibben MM, Kerbusch T, Kettenes-Van Den Bosch JJ, Rodenhuis S, Beijnen JH. High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells Journal of Liquid Chromatography and Related Technologies. 23: 1725-1744. DOI: 10.1081/Jlc-100100448 |
0.406 |
|
| 1999 |
Schrama JG, Rodenhuis S. Dose-intensive chemotherapy for locally advanced breast cancer. Current Oncology Reports. 1: 23-30. PMID 11122794 DOI: 10.1007/S11912-999-0006-6 |
0.467 |
|
| 1999 |
Rodenhuis S, de Wit R, de Mulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Mandjes I, Kooi M, de Vries EG. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 10: 1467-73. PMID 10643538 DOI: 10.1023/A:1008328012040 |
0.499 |
|
| 1999 |
Blay JY, Judson I, Rodenhuis S, Hermans C, Smith M, van Glabbeke M, Verweij J. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anti-Cancer Drugs. 10: 873-7. PMID 10630354 DOI: 10.1097/00001813-199911000-00002 |
0.386 |
|
| 1999 |
de Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. International Journal of Cancer. Journal International Du Cancer. 83: 831-3. PMID 10597204 DOI: 10.1002/(Sici)1097-0215(19991210)83:6<831::Aid-Ijc24>3.0.Co;2-O |
0.469 |
|
| 1999 |
Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van' t Veer LJ, Rodenhuis S. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Research and Treatment. 56: 219-31. PMID 10573113 DOI: 10.1023/A:1006261731125 |
0.318 |
|
| 1999 |
Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, Lorigan PC, Leyvraz S, Hermans C, van Glabbeke M, Verweij J. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer (Oxford, England : 1990). 35: 410-2. PMID 10448291 DOI: 10.1016/S0959-8049(98)00403-1 |
0.396 |
|
| 1999 |
Westermann AM, Holtkamp MM, Linthorst GA, van Leeuwen L, Willemse EJ, van Dijk WC, Nooijen WJ, Baars JW, Schornagel JH, Rodenhuis S. At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 10: 511-7. PMID 10415999 DOI: 10.1023/A:1026427724108 |
0.34 |
|
| 1999 |
Rodenhuis S, de Vries EG. [High-dose chemotherapy with stem cell support for solid tumors in adults]. Nederlands Tijdschrift Voor Geneeskunde. 143: 731-8. PMID 10347628 |
0.332 |
|
| 1999 |
van Gijn R, ten Bokkel Huinink WW, Rodenhuis S, Vermorken JB, van Tellingen O, Rosing H, van Warmerdam LJ, Beijnen JH. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. Anti-Cancer Drugs. 10: 17-23. PMID 10194543 DOI: 10.1097/00001813-199901000-00003 |
0.452 |
|
| 1999 |
Panday VR, van Warmerdam LJ, Huizing MT, Rodenhuis S, Schellens JH, Beijnen JH. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. Cancer Chemotherapy and Pharmacology. 43: 435-8. PMID 10100601 DOI: 10.1007/S002800050919 |
0.516 |
|
| 1999 |
Huitema AD, Holtkamp M, Tibben MM, Rodenhuis S, Beijnen JH. Sampling technique from central venous catheters proves critical for pharmacokinetic studies. Therapeutic Drug Monitoring. 21: 102-4. PMID 10051062 DOI: 10.1097/00007691-199902000-00016 |
0.374 |
|
| 1999 |
Rodenhuis S, De Vries E. Randomized studies of high-dose chemotherapy in high-risk breast cancer in The Netherlands European Journal of Cancer. 35: S219. DOI: 10.1016/S0959-8049(99)81281-7 |
0.432 |
|
| 1999 |
Holtkamp M, Westermann A, Linthorst G, Uyterlinde W, van Leeuwen L, Willemse E, Rodenhuis S. Managing patients at home during the aplastic phase of high dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) European Journal of Cancer. 35: S42. DOI: 10.1016/S0959-8049(99)80577-2 |
0.341 |
|
| 1998 |
van Maanen RJ, van Ooijen RD, Zwikker JW, Huitema AD, Rodenhuis S, Beijnen JH. Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography. Journal of Chromatography. B, Biomedical Sciences and Applications. 719: 103-12. PMID 9869370 DOI: 10.1016/S0378-4347(98)00381-8 |
0.397 |
|
| 1998 |
Huitema AD, Tibben MM, Kerbusch T, Zwikker JW, Rodenhuis S, Beijnen JH. Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. Journal of Chromatography. B, Biomedical Sciences and Applications. 716: 177-86. PMID 9824231 DOI: 10.1016/S0378-4347(98)00300-4 |
0.418 |
|
| 1998 |
Pedrazzoli P, Da Prada GA, Robustelli della Cuna G, Rodenhuis S, Dalesio O, Rutgers E. High-dose chemotherapy and stem-cell support in breast cancer (multiple letters) [1] Lancet. 352: 1220. PMID 9777858 |
0.308 |
|
| 1998 |
Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (London, England). 352: 515-21. PMID 9716055 DOI: 10.1016/S0140-6736(98)01350-6 |
0.494 |
|
| 1998 |
Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 9: 437-42. PMID 9636836 DOI: 10.1023/A:1008217129273 |
0.463 |
|
| 1998 |
de Vries EG, Meijs PJ, Rodenhuis S. Third-party payers and breast cancer study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 809. PMID 9469382 DOI: 10.1200/Jco.1998.16.2.809 |
0.357 |
|
| 1998 |
van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute. 90: 210-8. PMID 9462678 DOI: 10.1093/Jnci/90.3.210 |
0.451 |
|
| 1998 |
Rodenhuis S, Dalesio O, Rutgers E. High-dose chemotherapy and stem-cell support in breast cancer The Lancet. 352: 1220. DOI: 10.1016/S0140-6736(05)60556-9 |
0.422 |
|
| 1998 |
Rodenhuis S, De Vries EGE. Dutch studies of high-dose chemotherapy with hematopoietic progenitor cell support in high-risk breast cancer Bone Marrow Transplantation. 22: s91-s92. |
0.315 |
|
| 1997 |
Ten Bokkel Huinink WW, Lustig V, Dubbelman R, Hiemstra A, Rodenhuis S. Docetaxel alternating with epirubicin and cyclophosphamide: A feasibility study in breast cancer patients European Journal of Cancer Part A. 33: S23-S25. PMID 9486100 DOI: 10.1016/S0959-8049(97)90006-X |
0.486 |
|
| 1997 |
Westermann AM, Dubbelman R, Moolenaar WH, Beijnen J, Rodenhuis S. Successful intraperitoneal suramin treatment of peritoneal mesothelioma Annals of Oncology. 8: 801-802. PMID 9332690 DOI: 10.1023/A:1008231901539 |
0.353 |
|
| 1997 |
Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S. Growth factors in human ovarian cancer Cancer Treatment Reviews. 23: 113-131. PMID 9225962 DOI: 10.1016/S0305-7372(97)90024-4 |
0.397 |
|
| 1997 |
Ten Bokkel Huinink WW, Van Warmerdam LJC, Helmerhorst TJ, Schaefers MCW, Beijnen JH, Rodenhuis S. Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer Annals of Oncology. 8: 351-354. PMID 9209664 DOI: 10.1023/A:1008219618331 |
0.525 |
|
| 1997 |
Huizing MT, van Warmerdam LJC, Rosing H, Schaefers MCW, Lai A, Helmerhorst TJM, Veenhof CHN, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer Journal of Clinical Oncology. 15: 1953-1964. PMID 9164207 DOI: 10.1200/Jco.1997.15.5.1953 |
0.52 |
|
| 1997 |
de Vries EG, Mastenbroek CC, Rodenhuis S. High-dose chemotherapy for breast cancer. Annals of Internal Medicine. 126: 917-8. PMID 9163302 DOI: 10.7326/0003-4819-126-11-199706010-00022 |
0.403 |
|
| 1997 |
Rushing DA, De Vries EGE, Mastenbroek CC, Rodenhuis S, Gradishar WJ, Tallman MS. High-dose chemotherapy for breast cancer [4] (multiple letters) Annals of Internal Medicine. 126: 917-918. PMID 9163301 |
0.34 |
|
| 1997 |
Huinink WTB, Veenhof C, Huizing M, Rodenhuis S, Helmerhorst T, Dubbelman R, Dalesio O, Beijnen J, Winograd B. Carboplatin and paclitaxel in patients with advanced ovarian cancer: A dose-finding study Seminars in Oncology. 24: S2-31-S2-33. PMID 9045333 |
0.373 |
|
| 1997 |
van Enckevort P, TenVergert E, de Vries E, Rodenhuis S. PP65. Economic evaluation of high dose chemotherapy for breast cancer patients European Journal of Cancer. 33: S38. DOI: 10.1016/S0959-8049(97)85979-5 |
0.457 |
|
| 1997 |
Rodenhuis S, Richel D, Baars J, Schomagel J, Borger J, Koning C, Rutgers E. A randomized single-institution study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (CTC) in apical node-positive breast cancer European Journal of Cancer. 33: S217. DOI: 10.1016/S0959-8049(97)85731-0 |
0.431 |
|
| 1996 |
De Vries EGE, Rodenhuis S, Schouten HC, Hupperets PSGJ, Dolsma WV, Lebesque JV, Blijham GH, Bontenbal M, Mulder NH. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer Breast Cancer Research and Treatment. 39: 307-313. PMID 8877010 DOI: 10.1007/Bf01806158 |
0.451 |
|
| 1996 |
De Vries EGE, Ten Vergert EM, Mastenbroek CG, Dalesio O, Rodenhuis S. Breast cancer studies in the Netherlands [10] Lancet. 348: 407-408. PMID 8709754 DOI: 10.1016/S0140-6736(05)65026-X |
0.358 |
|
| 1996 |
Van Tellingen O, Kuck MT, Vlasveld LT, Rodenhuis S, Nooijen WJ, Beijnen JH. Unchanged pharmacokinetics of etoposide given by intraarterial hepatic infusion as compared with i.v. infusion Cancer Chemotherapy and Pharmacology. 38: 387-390. PMID 8674164 DOI: 10.1007/S002800050500 |
0.448 |
|
| 1996 |
Van Warmerdam LJC, Creemers GJ, Rodenhuis S, Rosing H, De Boer-Dennert M, Schellens JHM, Ten Bokkel Huinink WW, Davies BE, Maes RAA, Verweij J, Beijnen JH. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure Cancer Chemotherapy and Pharmacology. 38: 254-260. PMID 8646800 DOI: 10.1007/S002800050479 |
0.479 |
|
| 1996 |
Van Der Wall E, Rutgers EJT, Holtkamp MJ, Baars JW, Schornagel JH, Peterse JL, Beijnen JH, Rodenhuis S. Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients British Journal of Cancer. 73: 1080-1085. PMID 8624267 DOI: 10.1038/Bjc.1996.208 |
0.576 |
|
| 1996 |
Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach IC, Schornagel JH. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer Journal of Clinical Oncology. 14: 1473-1483. PMID 8622061 DOI: 10.1200/Jco.1996.14.5.1473 |
0.429 |
|
| 1996 |
Van Warmerdam LJC, Rodenhuis S, Van Der Wall E, Maes RAA, Beijnen JH. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support British Journal of Cancer. 73: 979-984. PMID 8611435 DOI: 10.1038/Bjc.1996.191 |
0.54 |
|
| 1996 |
Jonkman-de Vries J, Herben V, van Tellingen O, Dubbelman A, ten Bokkel Huinink W, Rodenhuis S, Bult A, Beijnen J. Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules Clinical Drug Investigation. 12: 298-307. DOI: 10.2165/00044011-199612060-00003 |
0.476 |
|
| 1996 |
Rutgers E, Richel D, Baars J, Schornagel J, Borger J, Koning C, Rodenhuis S. PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer European Journal of Cancer. 32: 34. DOI: 10.1016/0959-8049(96)84164-5 |
0.421 |
|
| 1996 |
Van Der Wall E, Schaake-Koning CCE, Van Zandwijk N, Baars JW, Schornagel JH, Richel DJ, Rutgers EJT, Borger JH, Beijnen JH, Rodenhuis S. The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: A preliminary analysis European Journal of Cancer Part A. 32: 1483-1485. DOI: 10.1016/0959-8049(96)00129-3 |
0.549 |
|
| 1995 |
Van Warmerdam LJC, Van Tellingen O, Ten Bokkel Huinink WW, Rodenhuis S, Maes RAA, Beijnen JH. Monitoring carboplatin concentrations in saliva: A replacement for plasma ultrafiltrate measurements? Therapeutic Drug Monitoring. 17: 465-470. PMID 8585109 DOI: 10.1097/00007691-199510000-00006 |
0.47 |
|
| 1995 |
van Warmerdam LJC, Rodenhuis S, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin Cancer Chemotherapy and Pharmacology. 37: 266-270. PMID 8529288 DOI: 10.1007/Bf00688327 |
0.428 |
|
| 1995 |
van der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy regimens for solid tumors Cancer Treatment Reviews. 21: 105-132. PMID 7758003 DOI: 10.1016/0305-7372(95)90023-3 |
0.554 |
|
| 1995 |
van Warmerdam LJC, Rodenhuis S, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. The use of the Calvert formula to determine the optimal carboplatin dosage Journal of Cancer Research and Clinical Oncology. 121: 478-486. PMID 7642691 DOI: 10.1007/Bf01218365 |
0.507 |
|
| 1995 |
Rodenhuis S, van der Wall E, ten Bokkel Huinink WW, Schornagel JH, Richel DJ, Tom Vlasveld L. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer Cancer Investigation. 13: 355-362. PMID 7627721 DOI: 10.3109/07357909509031915 |
0.463 |
|
| 1995 |
Van Warmerdam LJC, Ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RAA, Beijnen JH. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion Journal of Clinical Oncology. 13: 1768-1776. PMID 7602366 DOI: 10.1200/Jco.1995.13.7.1768 |
0.451 |
|
| 1995 |
Zandwijk Nv, Mooi WJ, Rodenhuis S. Prognostic factors in NSCLC. Recent experiences Lung Cancer. 12: S27-S33. PMID 7551931 DOI: 10.1016/0169-5002(95)00418-Z |
0.3 |
|
| 1995 |
Van der Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schornagel JH, Richel DJ, Rutgers EJT, Slaper-Cortenbach ICM, Van der Schoot CE, Rodenhuis S. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: A practical approach British Journal of Cancer. 71: 857-862. PMID 7536025 DOI: 10.1038/Bjc.1995.165 |
0.476 |
|
| 1995 |
Herben V, ten Bokkel Huinink W, Rodenhuis S, Schornagel J, Beijnen J. 940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E) European Journal of Cancer. 31: S196. DOI: 10.1016/0959-8049(95)96189-K |
0.474 |
|
| 1995 |
Rodenhuis S, van der Wall E, Schornagel J, Holtkamp M, Nooijen W, Baars J. 12 Multiple courses of high-dose alkylating therapy with autologous stem cell support European Journal of Cancer. 31: S3-S4. DOI: 10.1016/0959-8049(95)95264-7 |
0.468 |
|
| 1995 |
Baars JW, Rodenhuis S, Van Der Wall E, Schornagel JH. High dose chemotherapy in breast cancer reviewed Nederlands Tijschrift Voor De Klinische Chemie. 20: 288-293. |
0.329 |
|
| 1994 |
van Warmerdam LJC, Rodenhuis S, van Tellingen O, Maes RAA, Beijnen JH. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination Cancer Chemotherapy and Pharmacology. 35: 179-181. PMID 7987998 DOI: 10.1007/Bf00686644 |
0.526 |
|
| 1994 |
Sips JHM, van Tellingen O, Nooijen WJ, Rodenhuis S, Ten Bokkel Huinink WW, Beijnen JH. The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid Cancer Chemotherapy and Pharmacology. 35: 144-148. PMID 7987991 DOI: 10.1007/Bf00686637 |
0.413 |
|
| 1993 |
Taal BG, Ten Bokkel Huinink WW, Rodenhuis S. Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: A dose-finding study Annals of Oncology. 4: 81-82. PMID 8435369 DOI: 10.1093/Oxfordjournals.Annonc.A058369 |
0.412 |
|
| 1993 |
Van Der Wall E, Richel DJ, Kusumanto YH, Rutgers EJT, Schornagel JH, Schaake-koning CCE, Peterse JL, Rodenhuis S. Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer Annals of Oncology. 4: 791-792. PMID 8280661 DOI: 10.1093/Oxfordjournals.Annonc.A058667 |
0.439 |
|
| 1993 |
Vermorken JB, Verweij J, De Mulder PHM, Cognetti F, Clavel M, Rodenhuis S, Kirkpatrick A, Snow GB. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group Annals of Oncology. 4: 785-788. PMID 8280659 DOI: 10.1093/Oxfordjournals.Annonc.A058665 |
0.317 |
|
| 1993 |
Taal BG, Ten Bokkel Huinink WW, Rodenhuis S. Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer European Journal of Cancer. 29: 1916-1917. PMID 8260256 DOI: 10.1016/0959-8049(93)90560-3 |
0.328 |
|
| 1993 |
Richel DJ, Van der Wall E, Slaper J, Van der Schoot E, Rodenhuis S. Peripheral blood stem cell (PBSC) mobilization and transplantation (PSCT) in patients with malignant lymphomas and solid tumors International Journal of Artificial Organs. 16: 71-75. PMID 7516919 DOI: 10.1177/039139889301605S13 |
0.358 |
|
| 1993 |
Rodenhuis S, Baars JW, Schornagel JH, Vlasveld LT, Mandjes I, Pinedo HM, Richel DJ. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 3: 855-60. PMID 1286049 DOI: 10.1093/OXFORDJOURNALS.ANNONC.A058111 |
0.366 |
|
| 1993 |
van Zandwijk N, Rodenhuis S, Mooi WJ. New treatment opportunities in non-small cell lung cancer Lung Cancer. 9: 109-116. DOI: 10.1016/0169-5002(93)90175-W |
0.335 |
|
| 1992 |
Vlasveld LT, Rankin EM, Hekman A, Rodenhuis S, Beijnen JH, Hilton AM, Dubbelman AC, Vyth-Dreese FA, Melief CJ. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. British Journal of Cancer. 65: 744-50. PMID 1586602 DOI: 10.1038/Bjc.1992.157 |
0.511 |
|
| 1992 |
Beijnen JH, Vlasveld LT, Wanders J, ten Bokkel Huinink WW, Rodenhuis S. Effect of cisplatin-containing chemotherapy on lithium serum concentrations. The Annals of Pharmacotherapy. 26: 488-90. PMID 1576384 DOI: 10.1177/106002809202600406 |
0.419 |
|
| 1992 |
Rodenhuis S, Vlasveld LT, Dubbelman R, Roodbergen R, Schornagel JH, Wanders J, Israels SP, Bais E, Ten Bokkel Huinink WW, Richel DJ. Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 3: 463-7. PMID 1498065 DOI: 10.1093/Oxfordjournals.Annonc.A058235 |
0.47 |
|
| 1992 |
Huinink WWtB, Dalesio O, Rodenhuis S, Dubbelman R, Hilton A, Franklin H, Koier I, Tinteren Hv, Burg MELvd, Oosterom ATv, Neijt JP, Guastalla JP, George M. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. Seminars in Oncology. 19: 99-101. DOI: 10.5555/Uri:Pii:009377549290018V |
0.464 |
|
| 1991 |
Beijnen JH, Smith BR, Keijer WJ, van Gijn R, ten Bokkel Huinink WW, Vlasveld LT, Rodenhuis S, Underberg WJ. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. Journal of Pharmaceutical and Biomedical Analysis. 8: 789-94. PMID 2100624 DOI: 10.1016/0731-7085(90)80122-6 |
0.4 |
|
| 1991 |
Stoter G, Aamdal S, Rodenhuis S, Cleton FJ, Iacobelli S, Franks CR, Oskam R, Shiloni E. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 1687-91. PMID 1875225 DOI: 10.1200/Jco.1991.9.9.1687 |
0.366 |
|
| 1991 |
Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG. Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. European Journal of Cancer (Oxford, England : 1990). 27: 732-4. PMID 1829913 DOI: 10.1016/0277-5379(91)90176-E |
0.402 |
|
| 1991 |
Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, ten Bokkel Huinink WW, Somers R, Rümke P, Melief CJ. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunology, Immunotherapy : Cii. 32: 364-72. PMID 1706642 DOI: 10.1007/Bf01741331 |
0.356 |
|
| 1990 |
Vlasveld LT, Beynen JH, Boogerd W, Ten Bokkel Huinink WW, Rodenhuis S. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 25: 382-3. PMID 2407368 DOI: 10.1007/Bf00686244 |
0.391 |
|
| 1990 |
Ho AD, Thaler J, Stryckmans P, Coiffier B, Luciani M, Sonneveld P, Lechner K, Rodenhuis S, Peetermans ME, deCataldo F. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. Journal of the National Cancer Institute. 82: 1416-20. PMID 2388293 DOI: 10.1093/JNCI/82.17.1416 |
0.312 |
|
| 1988 |
Slebos RJ, de Graeff A, Van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S. Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. European Journal of Cancer & Clinical Oncology. 24: 1529-30. PMID 3181273 DOI: 10.1016/0277-5379(88)90347-1 |
0.327 |
|
| 1988 |
de Graeff A, Slebos RJ, Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemotherapy and Pharmacology. 22: 325-32. PMID 3048763 DOI: 10.1007/Bf00254240 |
0.313 |
|
| 1984 |
Rodenhuis S, Mulder NH, Sleijfer DT, Schraffordt Koops H, Van de Grampel JC. Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule. European Journal of Cancer & Clinical Oncology. 20: 645-9. PMID 6539701 DOI: 10.1016/0277-5379(84)90011-7 |
0.406 |
|
| 1984 |
Rodenhuis S, Van Den Heuvel WJA, Annyas AA, Schraffordt Koops H, Sleijfer DT, Mulder NH. Patient motivation and informed consent in a phase I study of an anticancer agent European Journal of Cancer and Clinical Oncology. 20: 457-462. PMID 6539201 DOI: 10.1016/0277-5379(84)90229-3 |
0.311 |
|
| 1983 |
Rodenhuis S, Mulder NH, Sleijfer DT, Koops HS, van de Grampel JC. Phase I clinical trial of (NPAz2)2NSOAz: 'SOAz'. Cancer Chemotherapy and Pharmacology. 10: 178-81. PMID 6861263 DOI: 10.1007/Bf00255757 |
0.467 |
|
| 1983 |
Rodenhuis S, Scaf AH, Mulder NH, Sleijfer DT, Beneken genaamd Kolmer MH, Uges DR, van de Grampel JC. Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'. Cancer Chemotherapy and Pharmacology. 10: 174-7. PMID 6861262 DOI: 10.1007/Bf00255756 |
0.376 |
|
| 1983 |
Beneken genaamd Kolmer MH, Rodenhuis S, van de Grampel JC, Uges DR. Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man. Cancer Chemotherapy and Pharmacology. 10: 170-3. PMID 6861261 DOI: 10.1007/Bf00255755 |
0.371 |
|
| Show low-probability matches. |
